Moderna Shares Gain 11.04% Ahead of Melanoma Trial Data
Image: TokenPost
The stock closed at $242.08 on Oct. 20, about 284.5% above its Aug. 18 close, as investors await detailed Phase 3 results.
Read the full story on TokenPostBeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.
